Submission Details
| 510(k) Number | K240279 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 01, 2024 |
| Decision Date | May 01, 2024 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
K240279 is an FDA 510(k) clearance for the VIDAS TBI (GFAP, UCH-L1), a Brain Trauma Assessment Test (Class II — Special Controls, product code QAT), submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on May 1, 2024, 90 days after receiving the submission on February 1, 2024. This device falls under the Immunology review panel. Regulated under 21 CFR 866.5830.
| 510(k) Number | K240279 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | February 01, 2024 |
| Decision Date | May 01, 2024 |
| Days to Decision | 90 days |
| Submission Type | Traditional |
| Review Panel | Immunology (IM) |
| Summary | Summary PDF |
| Product Code | QAT — Brain Trauma Assessment Test |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.5830 |
| Definition | Intended For In Vitro Diagnostic Use As An Aid In The Evaluation Of Patients With Suspected Mild Traumatic Brain Injury (tbi) In Conjunction With Other Clinical Information To Assist In Determining The Need For Radiologic (e.g., Ct, Mr) Head Imaging Per Current Standard Of Care |